medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2017, Number 07-08

<< Back Next >>

Medicina & Laboratorio 2017; 23 (07-08)

Clinical utility of anti-mullerian hormone measurement in children

Lasprilla-Tovar JD, Henao-Ochoa C, Alfaro-Velásquez JM, Campuzano-Maya G

Language: Spanish
References: 103
Page: 311-330
PDF size: 634.08 Kb.


ABSTRACT

The antimullerian hormone, initially referred as mullerian inhibitory substance, is a 12.5 kDa homodimeric glycoprotein, belonging to the transforming growth factor beta (TGF-β) family that playing a crucial role in male sexual differentiation by favoring regression of the Mullerian ducts. Since their production in the male is mainly by the immature Sertoli cells, in the last decades its usefulness has growth beyond the evaluation of the ovarian function and female fertility treatments, which has allowed evaluating the testicular function in male and affections such as hypogonadism, disorders of sexual differentiation, pathological puberty, cryptorchidism and others clinical conditions reviewed in this manuscript. In addition, this review describes the physiological role of the antimüllerian hormone in the prepubertal testes and the laboratory tests available for its measurement.


REFERENCES

  1. Josso N, Rey RA, Picard J-Y. Anti-müllerian Hormone: A Valuable Addition to the Toolbox of the Pediatric Endocrinologist. Int J Endocrinol 2013; 2013: 12.

  2. Pepinsky RB, Sinclair LK, Chow EP, Mattaliano RJ, Manganaro TF, Donahoe PK, et al. Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. J Biol Chem 1988; 263: 18961-18964.

  3. di Clemente N, Jamin SP, Lugovskoy A, Carmillo P, Ehrenfels C, Picard JY, et al. Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta. Mol Endocrinol 2010; 24: 2193- 2206.

  4. Edelsztein NY, Grinspon RP, Schteingart HF, Rey RA. Anti- Mullerian hormone as a marker of steroid and gonadotropin action in the testis of children and adolescents with disorders of the gonadal axis. Int J Pediatr Endocrinol 2016; 2016: 20.

  5. Lee MM, Donahoe PK. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev 1993; 14: 152-164.

  6. Weintraub A, Eldar-Geva T. Anti-Mullerian Hormone (AMH) Determinations in the Pediatric and Adolescent Endocrine Practice. Pediatr Endocrinol Rev 2017; 14: 364-370.

  7. Imbeaud S, Faure E, Lamarre I, Mattei MG, di Clemente N, Tizard R, et al. Insensitivity to anti-mullerian hormone due to a mutation in the human anti-mullerian hormone receptor. Nat Genet 1995; 11: 382-388.

  8. Josso N, Clemente N. Transduction pathway of anti-Mullerian hormone, a sex-specific member of the TGF-beta family. Trends Endocrinol Metab 2003; 14: 91-97.

  9. Lindhardt-Johansen M, Hagen CP, Johannsen TH, Main KM, Picard J-Y, Jorgensen A, et al. Anti-müllerian Hormone and Its Clinical Use in Pediatrics with Special Emphasis on Disorders of Sex Development. Int J Endocrinol 2013; 2013: 10.

  10. Visser J. AMH signaling: From receptor to target gene. Mol Cell Endocrinol 2003; 211: 65-73.

  11. di Clemente N, Belville C. Anti-Mullerian hormone receptor defect. Best Pract Res Clin Endocrinol Metab 2006; 20: 599-610.

  12. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab 2011; 25: 221-238.

  13. Valeri C, Schteingart HF, Rey RA. The prepubertal testis: biomarkers and functions. Curr Opin Endocrinol Diabetes Obes 2013; 20: 224-233.

  14. Henao-Ochoa C, Lasprilla-Tovar JD, Alfaro-Velásquez JM, Campuzano-Maya G. Utilidad clínica de la medición de la hormona antimülleriana en las mujeres. Medicina & Laboratorio 2017; 23: 213-236.

  15. Lasala C, Carre-Eusebe D, Picard JY, Rey R. Subcellular and molecular mechanisms regulating anti-Mullerian hormone gene expression in mammalian and nonmammalian species. DNA Cell Biol 2004; 23: 572-585.

  16. Lasala C, Schteingart HF, Arouche N, Bedecarras P, Grinspon RP, Picard JY, et al. SOX9 and SF1 are involved in cyclic AMP-mediated upregulation of anti-Mullerian gene expression in the testicular prepubertal Sertoli cell line SMAT1. Am J Physiol Endocrinol Metab 2011; 301: E539- 547.

  17. Lukas-Croisier C, Lasala C, Nicaud J, Bedecarras P, Kumar TR, Dutertre M, et al. Follicle-stimulating hormone increases testicular Anti-Mullerian hormone (AMH) production through sertoli cell proliferation and a nonclassical cyclic adenosine 5’-monophosphate-mediated activation of the AMH Gene. Mol Endocrinol 2003; 17: 550-561.

  18. Bergada I, Milani C, Bedecarras P, Andreone L, Ropelato MG, Gottlieb S, et al. Time course of the serum gonadotropin surge, inhibins, and anti-Mullerian hormone in normal newborn males during the first month of life. J Clin Endocrinol Metab 2006; 91: 4092-4098.

  19. Forest MG, Sizonenko PC, Cathiard AM, Bertrand J. Hypophyso-gonadal function in humans during the first year of life. 1. Evidence for testicular activity in early infancy. J Clin Invest 1974; 53: 819-828.

  20. Grinspon RP, Loreti N, Braslavsky D, Bedecarras P, Ambao V, Gottlieb S, et al. Sertoli cell markers in the diagnosis of paediatric male hypogonadism. J Pediatr Endocrinol Metab 2012; 25: 3-11.

  21. Aksglaede L, Sorensen K, Boas M, Mouritsen A, Hagen CP, Jensen RB, et al. Changes in anti-Mullerian hormone (AMH) throughout the life span: a population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. J Clin Endocrinol Metab 2010; 95: 5357-5364.

  22. Bergada I, Rojas G, Ropelato G, Ayuso S, Bergada C, Campo S. Sexual dimorphism in circulating monomeric and dimeric inhibins in normal boys and girls from birth to puberty. Clin Endocrinol (Oxf) 1999; 51: 455-460.

  23. Young J, Chanson P, Salenave S, Noel M, Brailly S, O’Flaherty M, et al. Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005; 90: 724-728.

  24. Nistal M, Abaurrea MA, Paniagua R. Morphological and histometric study on the human Sertoli cell from birth to the onset of puberty. J Anat 1982; 134: 351-363.

  25. Cassorla FG, Golden SM, Johnsonbaugh RE, Heroman WM, Loriaux DL, Sherins RJ. Testicular volume during early infancy. J Pediatr 1981; 99: 742-743.

  26. Joustra SD, van der Plas EM, Goede J, Oostdijk W, Delemarre- van de Waal HA, Hack WW, et al. New reference charts for testicular volume in Dutch children and adolescents allow the calculation of standard deviation scores. Acta Paediatr 2015; 104: e271-278.

  27. Sharpe RM, McKinnell C, Kivlin C, Fisher JS. Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. Reproduction 2003; 125: 769-784.

  28. Rey R, Lordereau-Richard I, Carel JC, Barbet P, Cate RL, Roger M, et al. Anti-müllerian hormone and testosterone serum levels are inversely during normal and precocious pubertal development. J Clin Endocr Metab 1993; 77: 1220-1226.

  29. Rey R. Endocrine, paracrine and cellular regulation of postnatal anti-mullerian hormone secretion by sertoli cells. Trends Endocrinol Metab 1998; 9: 271-276.

  30. Josso N, Rey R, Picard JY. Testicular anti-Mullerian hormone: clinical applications in DSD. Semin Reprod Med 2012; 30: 364-373.

  31. De Santa Barbara P, Bonneaud N, Boizet B, Desclozeaux M, Moniot B, Sudbeck P, et al. Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Mullerian hormone gene. Mol Cell Biol 1998; 18: 6653-6665.

  32. Viger RS, Mertineit C, Trasler JM, Nemer M. Transcription factor GATA-4 is expressed in a sexually dimorphic pattern during mouse gonadal development and is a potent activator of the Mullerian inhibiting substance promoter. Development 1998; 125: 2665-2675.

  33. Hossain A, Saunders GF. Role of Wilms Tumor 1 (WT1) in the Transcriptional Regulation of the Mullerian-Inhibiting Substance Promoter1. Biol Reprod 2003; 69: 1808-1814.

  34. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996; 81: 571-576.

  35. Rey R, Lukas-Croisier C, Lasala C, Bedecarras P. AMH/ MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol 2003; 211: 21-31.

  36. Grinspon RP, Rey RA. Anti-mullerian hormone and sertoli cell function in paediatric male hypogonadism. Horm Res Paediatr 2010; 73: 81-92.

  37. Chemes HE, Rey RA, Nistal M, Regadera J, Musse M, Gonzalez-Peramato P, et al. Physiological androgen insensitivity of the fetal, neonatal, and early infantile testis is explained by the ontogeny of the androgen receptor expression in Sertoli cells. J Clin Endocrinol Metab 2008; 93: 4408-4412.

  38. Boukari K, Meduri G, Brailly-Tabard S, Guibourdenche J, Ciampi ML, Massin N, et al. Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development. J Clin Endocrinol Metab 2009; 94: 1818-1825.

  39. Berensztein EB, Baquedano MS, Gonzalez CR, Saraco NI, Rodriguez J, Ponzio R, et al. Expression of aromatase, estrogen receptor alpha and beta, androgen receptor, and cytochrome P-450scc in the human early prepubertal testis. Pediatr Res 2006; 60: 740-744.

  40. Omabe M, Ezeani M, Martin O. Clinical Utilities of Anti Mullerian Hormone. Sch J App Med Sci 2013; Vol 1: 606- 618.

  41. Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. Dis Markers 2016; 2016: 5246217.

  42. Wherrett DK. Approach to the Infant with a Suspected Disorder of Sex Development. Pediatr Clin North Am 2015; 62: 983-999.

  43. Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, Edwards Z, et al. Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (Revised 2015). Clin Endocrinol (Oxf) 2016; 84: 771-788.

  44. Ostrer H. Disorders of sex development (DSDs): an update. J Clin Endocrinol Metab 2014; 99: 1503-1509.

  45. Lee MM, Misra M, Donahoe PK, MacLaughlin DT. MIS/ AMH in the assessment of cryptorchidism and intersex conditions. Mol Cell Endocrinol 2003; 211: 91-98.

  46. Rey RA, Codner E, Iniguez G, Bedecarras P, Trigo R, Okuma C, et al. Low risk of impaired testicular Sertoli and Leydig cell functions in boys with isolated hypospadias. J Clin Endocrinol Metab 2005; 90: 6035-6040.

  47. Abduljabbar M, Taheini K, Picard JY, Cate RL, Josso N. Mutations of the AMH type II receptor in two extended families with persistent Mullerian duct syndrome: lack of phenotype/genotype correlation. Horm Res Paediatr 2012; 77: 291-297.

  48. Josso N, Belville C, di Clemente N, Picard JY. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum Reprod Update 2005; 11: 351-356.

  49. Lang-Muritano M, Biason-Lauber A, Gitzelmann C, Belville C, Picard Y, Schoenle EJ. A novel mutation in the anti-mullerian hormone gene as cause of persistent mullerian duct syndrome. Eur J Pediatr 2001; 160: 652-654.

  50. Rey R. Anti-müllerian hormone in disorders of sex determination and differentiation. Arq Bras Endocrinol Metabol 2005; 49: 26-36.

  51. Grinspon RP, Nevado J, Mori Alvarez Mde L, Del Rey G, Castera R, Venara M, et al. 46,XX ovotesticular DSD associated with a SOX3 gene duplication in a SRY-negative boy. Clin Endocrinol (Oxf) 2016; 85: 673-675.

  52. Rey RA, Belville C, Nihoul-Fekete C, Michel-Calemard L, Forest MG, Lahlou N, et al. Evaluation of gonadal function in 107 intersex patients by means of serum antimullerian hormone measurement. J Clin Endocrinol Metab 1999; 84: 627-631.

  53. Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res 2010; 1: 297-301.

  54. Bonomi M, Libri DV, Guizzardi F, Guarducci E, Maiolo E, Pignatti E, et al. New understandings of the genetic basis of isolated idiopathic central hypogonadism. Asian J Androl 2012; 14: 49-56.

  55. Viswanathan V, Eugster EA. Etiology and Treatment of Hypogonadism in Adolescents. Pediatr Clin North Am 2011; 58: 1181-1200.

  56. Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother 2014; 15: 1247-1264.

  57. Adan L, Lechevalier P, Couto-Silva AC, Boissan M, Trivin C, Brailly-Tabard S, et al. Plasma inhibin B and antimullerian hormone concentrations in boys: discriminating between congenital hypogonadotropic hypogonadism and constitutional pubertal delay. Med Sci Monit 2010; 16: CR511-517.

  58. Coutant R, Biette-Demeneix E, Bouvattier C, Bouhours-Nouet N, Gatelais F, Dufresne S, et al. Baseline inhibin B and anti-Mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. J Clin Endocrinol Metab 2010; 95: 5225-5232.

  59. Young J, Rey R, Couzinet B, Chanson P, Josso N, Schaison G. Antimullerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1999; 84: 2696-2699.

  60. Nieschlag E. Klinefelter syndrome: the commonest form of hypogonadism, but often overlooked or untreated. Dtsch Arztebl Int 2013; 110: 347-353.

  61. Groth KA, Skakkebaek A, Host C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome--a clinical update. J Clin Endocrinol Metab 2013; 98: 20-30.

  62. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter’s syndrome. Lancet 2004; 364: 273-283.

  63. Bastida MG, Rey RA, Bergada I, Bedecarras P, Andreone L, del Rey G, et al. Establishment of testicular endocrine function impairment during childhood and puberty in boys with Klinefelter syndrome. Clin Endocrinol (Oxf) 2007; 67: 863-870.

  64. Lahlou N, Fennoy I, Carel JC, Roger M. Inhibin B and anti- Mullerian hormone, but not testosterone levels, are normal in infants with nonmosaic Klinefelter syndrome. J Clin Endocrinol Metab 2004; 89: 1864-1868.

  65. Aksglaede L, Christiansen P, Sorensen K, Boas M, Linneberg A, Main KM, et al. Serum concentrations of Anti-Mullerian Hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism. Acta Paediatr 2011; 100: 839-845.

  66. Pacenza N, Pasqualini T, Gottlieb S, Knoblovits P, Costanzo PR, Stewart Usher J, et al. Clinical Presentation of Klinefelter’s Syndrome: Differences According to Age. Int J Endocrinol 2012; 2012: 324835.

  67. Radmayr C, Dogan HS, Hoebeke P, Kocvara R, Nijman R, Stein R, et al. Management of undescended testes: European Association of Urology/European Society for Paediatric Urology Guidelines. J Pediatr Urol 2016; 12: 335-343.

  68. Niedzielski JK, Oszukowska E, Słowikowska-Hilczer J. Undescended testis – current trends and guidelines: a review of the literature. Arch Med Sci 2016; 12: 667-677.

  69. Penson D, Krishnaswami S, Jules A, McPheeters ML. Effectiveness of hormonal and surgical therapies for cryptorchidism: a systematic review. Pediatrics 2013; 131: e1897-1907.

  70. Blanco S, Gottlieb S, Grinspon R, Rey R. Criptorquidia: desde la embriología al tratamiento. Revista Médicas UIS 2015; 28: 371-380.

  71. Cortes D, Thorup JM, Visfeldt J. Cryptorchidism: aspects of fertility and neoplasms. A study including data of 1,335 consecutive boys who underwent testicular biopsy simultaneously with surgery for cryptorchidism. Horm Res 2001; 55: 21-27.

  72. Cortes D, Clasen-Linde E, Hutson JM, Li R, Thorup J. The Sertoli cell hormones inhibin-B and anti Mullerian hormone have different patterns of secretion in prepubertal cryptorchid boys. J Pediatr Surg 2016; 51: 475-480.

  73. Grinspon RP, Ropelato MG, Bedecarras P, Loreti N, Ballerini MG, Gottlieb S, et al. Gonadotrophin secretion pattern in anorchid boys from birth to pubertal age: pathophysiological aspects and diagnostic usefulness. Clin Endocrinol (Oxf) 2012; 76: 698-705.

  74. Elder JS. Ultrasonography is unnecessary in evaluating boys with a nonpalpable testis. Pediatrics 2002; 110: 748-751.

  75. Hrebinko RL, Bellinger MF. The limited role of imaging techniques in managing children with undescended testes. J Urol 1993; 150: 458-460.

  76. Lee MM, Donahoe PK, Silverman BL, Hasegawa T, Hasegawa Y, Gustafson ML, et al. Measurements of serum mullerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997; 336: 1480-1486.

  77. Misra M, MacLaughlin DT, Donahoe PK, Lee MM. Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism. J Clin Endocrinol Metab 2002; 87: 3598-3602.

  78. Rey RA, Venara M, Coutant R, Trabut J-B, Rouleau S, Lahlou N, et al. Unexpected mosaicism of R201H-GNAS1 mutant-bearing cells in the testes underlie macro-orchidism without sexual precocity in McCune–Albright syndrome. Hum Mol Genet 2006; 15: 3538-3543.

  79. Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med 2008; 358: 2366-2377.

  80. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013; 98: 2198- 2207.

  81. Brito VN, Spinola-Castro AM, Kochi C, Kopacek C, Silva PCAd, Guerra-Júnior G. Central precocious puberty: revisiting the diagnosis and therapeutic management. Arch Endocrinol Metab 2016; 60: 163-172.

  82. Grinspon RP, Andreone L, Bedecarrás P, Ropelato MG, Rey RA, Campo SM, et al. Male Central Precocious Puberty: Serum Profile of Anti-müllerian Hormone and Inhibin B before, during, and after Treatment with GnRH Analogue. Int J Endocrinol 2013; 2013: 823064.

  83. Abitbol L, Zborovski S, Palmert MR. Evaluation of delayed puberty: what diagnostic tests should be performed in the seemingly otherwise well adolescent? Arch Dis Child 2016; 101: 767-771.

  84. Wei C, Crowne EC. Recent advances in the understanding and management of delayed puberty. Arch Dis Child 2016; 101: 481-488.

  85. Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med 2012; 366: 443-453.

  86. Rohayem J, Nieschlag E, Kliesch S, Zitzmann M. Inhibin B, AMH, but not INSL3, IGF1 or DHEAS support differentiation between constitutional delay of growth and puberty and hypogonadotropic hypogonadism. Andrology 2015; 3: 882-887.

  87. Rey R, Sabourin JC, Venara M, Long WQ, Jaubert F, Zeller WP, et al. Anti-Mullerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol 2000; 31: 1202-1208.

  88. Venara M, Rey R, Bergada I, Mendilaharzu H, Campo S, Chemes H. Sertoli cell proliferations of the infantile testis: an intratubular form of Sertoli cell tumor? Am J Surg Pathol 2001; 25: 1237-1244.

  89. Chemaitilly W, Cohen LE. DIAGNOSIS OF ENDOCRINE DISEASE: Endocrine late-effects of childhood cancer and its treatments. Eur J Endocrinol 2017; 176: R183-R203.

  90. Patterson BC, Wasilewski-Masker K, Ryerson AB, Mertens A, Meacham L. Endocrine health problems detected in 519 patients evaluated in a pediatric cancer survivor program. J Clin Endocrinol Metab 2012; 97: 810-818.

  91. Levi M, Hasky N, Stemmer SM, Shalgi R, Ben-Aharon I. Anti-Mullerian Hormone Is a Marker for Chemotherapy- Induced Testicular Toxicity. Endocrinology 2015; 156: 3818-3827.

  92. Cuny A, Trivin C, Brailly-Tabard S, Adan L, Zerah M, Sainte-Rose C, et al. Inhibin B and anti-Mullerian hormone as markers of gonadal function after treatment for medulloblastoma or posterior fossa ependymoma during childhood. J Pediatr 2011; 158: 1016-1022 e1011.

  93. Baker ML, Metcalfe SA, Hutson JM. Serum levels of mullerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay. J Clin Endocrinol Metab 1990; 70: 11-15.

  94. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB, et al. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 1990; 70: 16-22.

  95. Josso N, Legeai L, Forest MG, Chaussain JL, Brauner R. An enzyme linked immunoassay for anti-mullerian hormone: a new tool for the evaluation of testicular function in infants and children. J Clin Endocrinol Metab 1990; 70: 23-27.

  96. Al-Qahtani A, Muttukrishna S, Appasamy M, Johns J, Cranfield M, Visser JA, et al. Development of a sensitive enzyme immunoassay for anti-Mullerian hormone and the evaluation of potential clinical applications in males and females. Clin Endocrinol (Oxf) 2005; 63: 267-273.

  97. Freour T, Mirallie S, Bach-Ngohou K, Denis M, Barriere P, Masson D. Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 2007; 375: 162-164.

  98. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE. Development of a second generation anti-Mullerian hormone (AMH) ELISA. J Immunol Methods 2010; 362: 51- 59.

  99. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011; 23: 411-420.

  100. Li HW, Wong BP, Ip WK, Yeung WS, Ho PC, Ng EH. Comparative evaluation of three new commercial immunoassays for anti-Mullerian hormone measurement. Hum Reprod 2016; 31: 2796-2802.

  101. Ansh Labs LLC. Ultra-Sensitive AMH/MIS ELISA. 2014. Disponible: https://www.anshlabs.com/wp-content/ uploads/inserts/AL105.pdf. Consultado: jun 2017.

  102. Roche Diagnostics International Ltd. Elecsys® AMH. 2014. Disponible: http://www.cobas.com/content/dam/ cobas_com/pdf/product/Elecsys%20AMH/Elecsys%20 AMH%20FactSheet.pdf. Consultado: jun 2017.

  103. Welsh P, Smith K, Nelson SM. A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay. Hum Reprod 2014; 29: 1035-1041.




2020     |     www.medigraphic.com